Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade Journal Article

   


Authors: Yoo, S. K.; Chowell, D.; Valero, C.; Morris, L. G. T.; Chan, T. A.
Article Title: Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade
Abstract: The effects of cytokine and protein stabilizing carriers, such as serum albumin, on tumor response to immune checkpoint blockade (ICB) is not well understood. By examining 1714 patients across 16 cancer types, we found that high pretreatment serum albumin level predicts favorable tumor radiographic response following ICB treatment in a dose-dependent fashion. Serum albumin is a candidate biomarker that can be combined with tumor mutational burden (TMB) for additional predictive capacity, and the tumor response rate to ICB was ~49% in the albumin-high/TMB-high group. © 2022, The Author(s).
Journal Title: npj Precision Oncology
Volume: 6
ISSN: 2397-768X
Publisher: Springer Nature  
Date Published: 2022-04-07
Start Page: 23
Language: English
DOI: 10.1038/s41698-022-00267-7
PROVIDER: scopus
PMCID: PMC8990074
PUBMED: 35393553
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85128044516&doi=10.1038%2fs41698-022-00267-7&partnerID=40&md5=7e05461c1bfa1d4ffa2dfaee40770b1c
Notes: Article -- Export Date: 2 May 2022 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Luc Morris
    278 Morris
  2. Cristina Valero Mayor
    58 Valero Mayor
Related MSK Work